Deferoxamine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DESFERAL | — | 1979-06-04 | fda.gov ↗ |
| Approved | US (FDA) | DESFERAL | — | 1968-04-01 | fda.gov ↗ |
Trials 32
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2006-04-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Deferoxamine Mesylate for Injection Usp tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2006-04-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Deferoxamine Mesylate for Injection Usp tevapharm.com ↗ |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | deferoxamine | “METHODS: We assessed cerebrovascular function (autoregulation, vasoreactivity, and neurovascular coupling) and serum concentrations of vascular endothelial growth factor and...” PMID 26304864 ↗ Jul 201541“We previously reduced MRI in rats through a combined antioxidant therapy (CAT) of ascorbic acid, N-acetylcysteine, and deferoxamine.” PMID 38973337 ↗ Jul 2024 “This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).” NCT02065492 ↗ “Patients will also continue the iron chelation therapy (Deferasirox, Deferiprone or Deferoxamine) in case of iron overload.” NCT07292259 ↗ “Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours” NCT04633889 ↗ “Drug: Deferoxamine Deferoxamine will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.” NCT01511848 ↗ |
| Known as | BA-29837 | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | BA-33112 | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Deferoxamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Deferoxamine (DFO) | “Deferoxamine (DFO)” NCT00901199 ↗ |
| Known as | Deferoxamine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | DEFEROXAMINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Deferoxamine mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | deferoxamine mesylate | “This study aims to evaluate the safety and tolerability and to explore the therapeutic efficacy of the iron chelator and antioxidant deferoxamine mesylate (DFO) in ischemic...” PMID 34439518 ↗ Aug 20215“The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days.” NCT06763055 ↗ “Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals.” NCT04566991 ↗ “All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.” NCT00598572 ↗ “Deferoxamine Mesylate is a generic drug, and there was no commercial or industrial support for the trial.” PMID 30898550 ↗ Mar 2019 |
| Known as | Deferoxamine methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Deferoxamini mesilas | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Desferal | “Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug, but is expensive and must be given by slow subcutaneous or intravenous infusion for...” NCT00350662 ↗8“Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload” NCT00901199 ↗ “Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg. Other Name: Desferal, DFO” NCT01511848 ↗ “Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug” NCT00349453 ↗ “Desferal (deferoxamine)” NCT00105495 ↗ |
| Known as | Desferoxamine b | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | desferrioxamine | “desferrioxamine injection 50 mg/kg” NCT00999349 ↗ |
| Known as | Desferrioxamine b | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Desferrioxamine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Desferrioxamine mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | Desferrioxamine mesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | DFO | “HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patients with severe transfusional myocardial siderosis...” PMID 25934475 ↗ May 201513“Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug, but is expensive and must be given by slow subcutaneous or intravenous infusion for...” NCT00350662 ↗ “The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a medicine called deferasirox (ICL670) with another medicine called...” NCT00600938 ↗ “This study aims to evaluate the safety and tolerability and to explore the therapeutic efficacy of the iron chelator and antioxidant deferoxamine mesylate (DFO) in ischemic...” PMID 34439518 ↗ Aug 2021 “Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals.” NCT04566991 ↗ “We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery” PMID 22187937 ↗ Dec 2011 “Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg. Other Name: Desferal, DFO” NCT01511848 ↗ “Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body” NCT00598572 ↗ “Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug” NCT00349453 ↗ “Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks” NCT04058197 ↗ “deferoxamine (DFO) given intrathecally (directly into the CSF)” NCT05184816 ↗ |
| Known as | Dfo-b | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | DFX | “treatment with N-acetylcysteine (NAC) plus deferoxamine (DFX) decreases the incidence of acute kidney injury (AKI).” PMID 27745551 ↗ Oct 20161“Culex cells were treated with either ferric ammonium citrate (FAC) or the iron chelator, deferoxamine (DFX).” PMID 28583206 ↗ Jun 2017 |
| Known as | NSC-268993 | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | NSC-527604 | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Known as | NSC-756718 | ChEMBL registry synonym — accepted as the source's own label CHEMBL556 ↗ |
| Action | Activate | “Deferoxamine is such a substance which stabilizes and activates HIF-1 by chelating iron.” NCT03137966 ↗ |
| Modality | Other / unclassified | “a hydrophilic chelator” NCT04566991 ↗ |
| Route | Subcutaneous | “All patients received subcutaneous deferoxamine” NCT00000595 ↗ |